Journey Medical (DERM) Cash & Equivalents (2020 - 2026)

Journey Medical (DERM) has reported Cash & Equivalents for 7 consecutive years, with $25.6 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Cash & Equivalents rose 26.32% year-over-year to $25.6 million; the trailing twelve-month figure through Jun 2026 stood at $25.6 million (up 26.32% YoY), and the FY2025 full-year result was $24.1 million, up 18.69% from the prior year.
• Cash & Equivalents retreated to $25.6 million in Q2 2026 per DERM's latest filing, from $27.2 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $41.3 million in Q1 2022 and bottomed at $8.2 million in Q2 2023.
• Historically, Cash & Equivalents has averaged $25.9 million across 5 years, with a median of $24.8 million in 2023.
• The sharpest annual moves came in 2023 and 2024: Cash & Equivalents sank 78.4% in 2023, then soared 190.55% in 2024.
• Over 5 years, Cash & Equivalents stood at $32.0 million in 2022, then slipped by 14.26% to $27.4 million in 2023, then declined by 26.0% to $20.3 million in 2024, then gained by 18.69% to $24.1 million in 2025, then climbed by 6.4% to $25.6 million in 2026.
• According to Business Quant data, Cash & Equivalents over the past three periods registered $25.6 million, $27.2 million, and $24.1 million for Q2 2026, Q1 2026, and Q4 2025 respectively.